The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2 overexpressing breast carcinomas.
Jean-Sebastien Frenel
No relevant relationships to disclose
Manuel Jorge Rodrigues
No relevant relationships to disclose
Julien Peron
No relevant relationships to disclose
Vano Yann-Alexandre
No relevant relationships to disclose
Johanna Wassermann
No relevant relationships to disclose
Marc Debled
No relevant relationships to disclose
Francois Picaud
No relevant relationships to disclose
Laurence Albiges
No relevant relationships to disclose
Anne Vincent-Salomon
No relevant relationships to disclose
Paul H. Cottu
No relevant relationships to disclose